Riassunto: TEVIMBRA è stato approvato negli Stati Uniti per il trattamento di prima linea del carcinoma a cellule squamose dell'esofago in stadio avanzato, in combinazione con la chemioterapia
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 04 2025
0mins
Should l Buy ?
Source: Businesswire
- Company Name Change: BeiGene, Ltd. plans to change its name to BeOne Medicines Ltd.
- FDA Approval Announcement: The FDA has approved TEVIMBRA (tislelizumab-jsgr) for first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma expressing PD-L1 (≥1), in combination with platinum-based chemotherapy.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
